Quantcast

Latest Genentech Inc. Stories

2008-12-04 08:00:00

LAUSANNE, Switzerland, December 4 /PRNewswire/ -- AC Immune SA, a leader in Alzheimer's disease drug development, announced today that the World Economic Forum has elected AC Immune as Technology Pioneer 2009 for its accomplishments as an innovation leader and for its breakthrough technologies that can have a deep impact on business and society. Furthermore, AC Immune released that it has reached significant clinical milestones in the development of innovative therapies against...

2008-11-07 03:00:04

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva(R) (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. There were no new or unexpected safety signals in the study and adverse...

448cf0ef31b2e3c7b94f3914b71180c1
2008-11-06 17:13:32

Scientists have reported new clues on how to treat spinal cord and brain injuries. In lab tests, researchers were successfully able to control regrowth of nerve cells in mice by turning off proteins responsible for cell growth. "This is the first time it has been possible to see such significant regeneration by manipulating single molecules," Zhigang He of Children's Hospital Boston, whose study appears in the journal Science, said in a statement. He and his colleagues foresee two main...

2008-11-03 09:00:06

Genentech, Inc. (NYSE:DNA) today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin(R) (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical...

2008-10-27 09:00:11

Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that Rituxan(R) (rituximab) data including results from Phase II and III studies of Rituxan in patients with moderately-to-severely active rheumatoid arthritis (RA) will be featured in two podium presentations and eight poster presentations at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco this week. Among the studies being presented are a Phase III controlled re-treatment...

2008-10-21 09:00:54

NERVIANO, Italy, October 21 /PRNewswire/ -- Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced a new multi-year agreement with Genentech, Inc. This new research agreement is the second collaboration agreement signed between Genentech and NMS in less than twelve months. The two Companies will collaborate in the discovery of antibody drug...

2008-10-20 03:00:08

Genentech, Inc. (NYSE:DNA) today announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin(R) (bevacizumab) plus chemotherapy in patients with early-stage colon cancer will continue as planned. The NSABP's decision to continue the trial was based on a recommendation from an independent Data Monitoring Committee (DMC) after a planned interim analysis. The study of 2,710 patients is being...

2008-10-07 03:00:08

Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) today announced that a global Phase III study of Rituxan(R) (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL) compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent...

2008-10-06 03:00:07

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin(R) (bevacizumab) in combination with Tarceva(R) (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of...

2008-10-03 03:00:30

Genentech, Inc. (NYSE:DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX:ROG) have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule. The companies will be developing GA101, a humanized anti-CD20 monoclonal antibody engineered to increase both direct- and immune-mediated target cell death, for the potential treatment of hematological malignancies and other...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'